Health Canal - "Leading Treatments for Uveitis Found to be Similarly Effective, Increasing Patient Options"

Douglas A. Jabs, MD, MBA, Chair of the Department of Ophthalmology led the study comparing the two leading treatment approaches for the eye condition uveitis.

New York, NY
 – August 13, 2011  –– 

A team of researchers comparing the two leading treatment approaches for the eye condition uveitis, which is the fifth leading cause of blindness in the US, have found that a time-release corticosteroid implant placed surgically in the eye is similarly effective in treating the disease as anti-inflammatory corticosteroids and immunosuppressive drugs taken orally. "These results, showing similar effectiveness of the two treatment approaches really gives doctors and patients more options for choosing a treatment based upon their individual circumstances," said Douglas A. Jabs, MD, MBA, Chair of the Department of Ophthalmology at Mount Sinai School of Medicine, who led the study. "With both approaches being shown to be similarly effective in preserving vision, patients, in consultation with their physicians, can select the treatment option that is right for them." Learn More